An observational study in Down Syndrome, sponsored by University Hospital, Grenoble. Recruiting at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by University Hospital, Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Down Syndrome with a site in France — 12 open to participants now, 12 under way, none of them phase 3. Down Syndrome · France.
Among the 40 studies in Down Syndrome with a site in France, this one is the 18th largest by planned enrollment of the 23 observational ones that give a count, is one of 4 that started in 2024, is one of 23 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 28th registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →12 of the 40 studies in Down Syndrome with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 3–29 · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
Aelis Farma · Sites in France, Italy, Spain
Ages 16–32
Hôpital le Vinatier · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 3–12
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 2
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 158 across 145 observational studies indexed under Down Syndrome.
Median enrollment 150 across the 17 interventional studies, 100 across the 23 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 40 have an industry lead sponsor. The 10 most frequent:
University Hospital, Grenoble is the lead sponsor of 838 studies on the registry; 208 are open to participants now.
University Hospital, Grenoble has 3 studies filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Down Syndrome with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061562University Hospital, GrenobleDown Syndrome, Physical Activity and Sleep Apnea | 2026-12-31 |
| NCT05970965Assistance Publique - Hôpitaux de ParisPeriodontitis and Inflammation in Children With Down Syndrome/Trisomy 21: Study on Biological Samples | 2027-04-30 |
| NCT06866925Hôpital le VinatiertDCS for Catatonic Depression in Down Syndrome: A Pilot Study | 2027-08-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies in Down Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To realize a sleep phenotyping in a population with Down syndrome, its determinants, and the consequences of these disorders, with a specific focus on sleep apnea syndrome.
Sleep disorders are widely observed in the Down's syndrome population, due to a number of risk factors, and can become established in early childhood. Diagnosis of sleep disorders in Down's syndrome is difficult and often delayed, which can contribute to poor health in children with Down's syndrome. Phenotyping sleep characteristics in this Down Syndrome population will enable early identification of the consequences of these disorders, with a specific focus on sleep apnea syndrome, whose origin is multisystemic.
Down syndrome is associated with numerous clinical expressions. The most frequent are deficits in cognitive development, autonomic nervous system dysfunctions, cardiovascular dysfunctions, and osteoarticular specificities. Taken together, these clinical features can lead to a sedentary and overweight lifestyle, directly responsible for the onset of early fatigue and effort limitation. Numerous co-morbidities are also reported, such as the presence of sleep apnea syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A cohort of participants (child, teenager, or adult), with or without sleep disorders
phenotyping of sleep in a population with Down's syndrome, its determinants, and the consequences of these disorders, with a specific focus on sleep apnea syndrome, whose origin is multisystemic
Diagnosis of Sleep Apnea Syndrome using calculation of apnea hypopnea index (AHI)\>15 events/h
Time frame: Visite 2: 2 nights
Sleep-disordered breathing associated with dysautonomia
Polysomnography
Time frame: Visite 2: 1 night
Sleep-disordered breathing associated with dysautonomia
Heart rate (beat per min) recording using a cardiofrequency meter to measure the RR interval (in milliseconds); measured over 3 nights max in an ecological environment
Time frame: Visite 2: up to 3 nights
Sleep-disordered breathing associated with dysautonomia
The variables used to assess the autonomic profile will be obtained by calculating LF and LF(low and high frequency in ms² and normalized units) spectral variations and the LF/HF ratio
Time frame: Visite 2: up to 3 nights
Sleep-disordered breathing associated with specific abnormalities of the biological work-up
Biological disturbances will be assessed by differences in thyroid function, and other biological variables (NFS, lipid and hormone levels, iron levels) in comparison with standards. This biological assessment is obtained by blood sampling.
Time frame: Visite 1: the morning before the physical activity
Sleep-disordered breathing associated with a specific cranial structure
The existence of cranial anatomical variations, in particular anomalies specific to the oral sphere (modification of the gonia angle (in degrees), and prognatism (in cm)) will be investigated by cephalometry.
Time frame: Day 0
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by questionnaires (scores).
Time frame: Day 0 and visite 1
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by actimetry (min per day)
Time frame: From inclusion to last visit of the patient: up to 90 days
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by anthropometric variables (Weight (kg)
Time frame: Day 0 and visite 1: 1 time
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by Height (m)
Time frame: Day 0 and visite 1: 1 time
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by BMI (kg/m²)
Time frame: Day 0 and visite 1: 1 time
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by determinants of physical fitness (measurement of strength (Newton)
Time frame: Visite 1: up to 1 hour
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by flexibility (cm)
Time frame: Visite 1: up to 1 hour
Sleep-disordered breathing associated with inadequate physical activity
Abnormalities in the physiological response to exercise (VO2 (in mL/kg/min) compared with the predicted value) will be investigated and linked to the level of physical activity measured by balance variables (seconds).
Time frame: Visite 1: up to 1 hour
Sleep-disordered breathing associated with inadequate physical activity
Effort response (% chronotropic response) will also be calculated to complete the autonomic profile.
Time frame: Visite 1: up to 1 hour
Sleep-disordered breathing associated with specific neurobehavioral disorders
A neurobehavioral profile assessment will be carried out using several tests, in order to verify the possible impact of TdS on cognitive function: * Intelligence quotient (Wechsler scale), if not previously performed (score) * Stroop task (inhibitory control) (score) * Reaction time using a light device (seconds) * Ability to perform a double cognitive-motor task, (score) * BRIEF questionnaire (to explore executive function) (score) * ADHD rating scale (to explore signs of attention deficit/hyperactivity disorder). (score)
Time frame: Day 0
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.
Of 40 non-industry observational studies under Down Syndrome, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 61. This study's planned 35 months is above that.
Counting every sponsor, half of 55 studies reached it within 34 months; a quarter within 19 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble →